


CLAIMS

What is claimed as new and desired to be protected by Letters Patent of the United


States is:

- 1 1. A polyamine having the structure



2 3. wherein, n can be 0 to 8 and the aminomethyl functionality can be ortho, meta or para
 4 substituted, R is hydrogen, -CH₃, -CH₂CH₃, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-
 5 aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminoctyl, N-methyl-2-aminoethyl, N-methyl-3-
 6 aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-
 7 methyl-7-aminoheptyl, N-methyl-8-aminoctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-
 8 ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-
 9 ethyl-8-aminoctyl and R₁ is a moiety selected from the group consisting of a hydrogen or a straight
 10 or branched C1-20 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when
 11 R =H, n=1 and the aminomethyl functionality is para substituted; an alicyclic; single or multi-ring
 12 aromatic; single or multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring
 13 aromatic; a single or multi-ring heterocyclic, a single or multi-ring heterocyclic-substituted aliphatic;
 14 an aliphatic-substituted aromatic; and halogenated forms thereof, and wherein said polyamine is a
 15 non-symmetrical xylene.

- 1 2. A polyamine having the structure




2 3. wherein n can be 0 to 8, and the aminomethyl functionality can be ortho, meta or para
 4 substituted, R is hydrogen -CH₃, -CH₂CH₃, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-
 5 aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminoctyl, N-methyl-2-aminoethyl, N-methyl-3-

6 aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-
 7 methyl-7-aminoheptyl, N-methyl-8-aminooctyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl,
 8 N-methyl-8-aminooctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-
 9 ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-ethyl-8-aminooctyl and R₁
 10 is a moiety selected from the group consisting of a hydrogen or a straight or branched C1-20
 11 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when R=H, n=1 and the
 12 aminomethyl functionality is para substituted; an alicyclic; single or multi-ring aromatic; single or
 13 multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring aromatic; a single or
 14 multi-ring heterocyclic, a single or multi-ring heterocyclic substituted aliphatic; an aliphatic-
 15 substituted aromatic; and halogenated forms thereof;

16 R₂ can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and R₄ may be
 17 the same or different and are independently selected from hydrogen, or fluorine;


18 and halogenated forms thereof, and wherein said polyamine is a non-symmetrical derivative
 19 of xylene.

1 3. A polyamine having the structure




3 wherein, m and n can be 0 to 7 independently, but m cannot equal n when R₁ equals R₂ and
 4 R₃ equals R₄, o can be 2 to 4, R can be independently selected from H, -CH₃ or -CH₂CH₃, R₁ and R₂
 5 can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and R₄ may be the same or
 6 different and are independently selected from hydrogen or fluorine, and wherein said polyamine is a
 7 non-symmetrical xylene.

1 4. A polyamine having the structure



3 wherein, R is hydrogen, -CH₃, or -CH₂CH₃, m and n can be 0 to 7 independently and o can
 4 be 2 to 4, R₂ can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and R₄ may be
 5 the same or different and are independently selected from hydrogen or fluorine.

1 5. A polyamine having the structure



3 wherein, R is hydrogen, -CH₃, or -CH₂CH₃, m can be 0 to 7, n can be 0 to 8 and o
 4 can be 2 to 4, R₂ can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and
 5 R₄ may be the same or different and are independently selected from hydrogen or fluorine.

1 6. The polyamine of any one of claims 1-5 wherein said structure is that of compounds
 2 A-Q, T and U as shown in Figure 1.

1 7. A pharmaceutical composition useful for treating a disease or condition in which the
 2 inhibition of cell growth or proliferation is desirable, comprising a polyamine according to any one
 3 of claims 1-6 and a pharmaceutically acceptable excipient, diluent or vehicle.


1 8. The composition of claim 7 wherein said excipient, diluent or vehicle is
 2 pharmaceutically or cosmetically acceptable.

1 9. The composition of claim 7 wherein said excipient, diluent or vehicle is for topical or
 2 intra-aural administration.


1 10. The composition of claim 7 formulated for intravenous, subcutaneous, intramuscular,
 2 intracranial, intraperitoneal, topical, transdermal, intravaginal, intranasal, intrabronchial,
 3 intracranial, intraocular, intraaural, rectal, or parenteral administration.

4

5 11. A method of treating one or more conditions associated with cellular proliferation
 6 comprising administration of a polyamine represented by at least one of the following structures:
 7



10 wherein, n can be 0 to 8 and the aminomethyl functionality can be ortho, meta or para
 11 substituted, R is hydrogen, -CH₃, -CH₂CH₃, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-
 12 aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminoctyl, N-methyl-2-aminoethyl, N-methyl-3-
 13 aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-
 14 methyl-7-aminoheptyl, N-methyl-8-aminoctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-
 15 ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-
 16 ethyl-8-aminoctyl and R₁ is a moiety selected from the group consisting of a hydrogen or a straight
 17 or branched C1-20 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when
 18 R =H, n=1 and the aminomethyl functionality is para substituted; an alicyclic; single or multi-ring
 19 aromatic; single or multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring
 20 aromatic; a single or multi-ring heterocyclic, a single or multi-ring heterocyclic-substituted aliphatic;
 21 an aliphatic-substituted aromatic; and halogenated forms thereof;




24 wherein n can be 0 to 8, and the aminomethyl functionality can be ortho, meta or para
 25 substituted, R is hydrogen -CH₃, -CH₂CH₃, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-
 26 aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminoctyl, N-methyl-2-aminoethyl, N-methyl-3-
 27 aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-
 28 methyl-7-aminoheptyl, N-methyl-8-aminoctyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl,
 29 N-methyl-8-aminoctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-
 30 ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-ethyl-8-aminoctyl and R₁
 31 is a moiety selected from the group consisting of a hydrogen or a straight or branched C1-20
 32 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when R=H, n=1 and the


32 aminomethyl functionality is para substituted; an alicyclic; single or multi-ring aromatic; single or
 33 multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring aromatic; a single or
 34 multi-ring heterocyclic, a single or multi-ring heterocyclic substituted aliphatic; an aliphatic-
 35 substituted aromatic; and halogenated forms thereof;

36 R₂ can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and R₄ may be
 37 the same or different and are independently selected from hydrogen, or fluorine;
 38 and halogenated forms thereof;


39



41 wherein, m and n can be 0 to 7 independently, but m cannot equal n when R₁ equals R₂ and
 42 R₃ equals R₄, o can be 2 to 4, R can be independently selected from H, -CH₃ or -CH₂CH₃, R₁ and R₂
 43 can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and R₄ may be the same or
 44 different and are independently selected from hydrogen or fluorine;



2 wherein, R is hydrogen, -CH₃, or -CH₂CH₃, m and n can be 0 to 7 independently and o can
 3 be 2 to 4, R₂ can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and R₄ may be
 4 the same or different and are independently selected from hydrogen or fluorine; and




2 wherein, R is hydrogen, -CH₃, or -CH₂CH₃, m can be 0 to 7, n can be 0 to 8 and o
 3 can be 2 to 4, R₂ can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and
 4 R₄ may be the same or different and are independently selected from hydrogen or fluorine.

12. The method of claim 11 wherein said administration is systemic.


13. The method of claim 11 wherein said administration is oral.

14. The method of claim 11 wherein said administration is via a time-release vehicle.

1 15. A method of inhibiting hair growth comprising topical administration to a subject in
2 need of hair growth inhibition of a polyamine represented by at least one of the following structures:




6 wherein, n can be 0 to 8 and the aminomethyl functionality can be ortho, meta or para
7 substituted, R is hydrogen, -CH₃, -CH₂CH₃, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-
8 aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminoctyl, N-methyl-2-aminoethyl, N-methyl-3-
9 aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-
10 methyl-7-aminoheptyl, N-methyl-8-aminoctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-
11 ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-
12 ethyl-8-aminoctyl and R₁ is a moiety selected from the group consisting of a hydrogen or a straight
13 or branched C1-20 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when
14 R =H, n=1 and the aminomethyl functionality is para substituted; an alicyclic; single or multi-ring
15 aromatic; single or multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring
16 aromatic; a single or multi-ring heterocyclic, a single or multi-ring heterocyclic-substituted aliphatic;
17 an aliphatic-substituted aromatic; and halogenated forms thereof;




20 wherein n can be 0 to 8, and the aminomethyl functionality can be ortho, meta or para
substituted, R is hydrogen -CH₃, -CH₂CH₃, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-


21 aminopentyl, 6-aminohexyl, 7-aminohexyl, 8-aminocetyl, N-methyl-2-aminoethyl, N-methyl-3-
 22 aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-
 23 methyl-7-aminohexyl, N-methyl-8-aminooctyl, N-methyl-6-aminohexyl, N-methyl-7-aminohexyl,
 24 N-methyl-8-aminooctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-
 25 ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminohexyl or N-ethyl-8-aminocetyl and R₁
 26 is a moiety selected from the group consisting of a hydrogen or a straight or branched C1-20
 27 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when R=H, n=1 and the
 28 aminomethyl functionality is para substituted; an alicyclic; single or multi-ring aromatic; single or
 29 multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring aromatic; a single or
 30 multi-ring heterocyclic, a single or multi-ring heterocyclic substituted aliphatic; an aliphatic-
 31 substituted aromatic; and halogenated forms thereof;
 32 R₂ can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and R₄ may be
 33 the same or different and are independently selected from hydrogen, or fluorine;
 34 and halogenated forms thereof;
 35



37 wherein, m and n can be 0 to 7 independently, but m cannot equal n when R₁ equals R₂ and
 38 R₃ equals R₄, o can be 2 to 4, R can be independently selected from H, -CH₃ or -CH₂CH₃, R₁ and R₂
 39 can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and R₄ may be the same or
 40 different and are independently selected from hydrogen or fluorine;




2 wherein, R is hydrogen, -CH₃, or -CH₂CH₃, m and n can be 0 to 7 independently and o can
 3 be 2 to 4, R₂ can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and R₄ may be
 4 the same or different and are independently selected from hydrogen or fluorine; and



2 wherein, R is hydrogen, -CH₃, or -CH₂CH₃, m can be 0 to 7, n can be 0 to 8 and o
 3 can be 2 to 4, R₂ can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and
 4 R₄ may be the same or different and are independently selected from hydrogen or fluorine.


5 16. The method of claim 15 wherein polyamine is formulated as a cosmetic.

1 17. A method of inhibiting hair loss (alopecia) comprising topical administration of a
 2 subject undergoing radiation or chemotherapy a polyamine represented by at least one of the
 3 following structures:



6 wherein, n can be 0 to 8 and the aminomethyl functionality can be ortho, meta or para
 7 substituted, R is hydrogen, -CH₃, -CH₂CH₃, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-
 8 aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminoctyl, N-methyl-2-aminoethyl, N-methyl-3-
 9 aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentyl, N-methyl-6-aminohexyl, N-
 10 methyl-7-aminoheptyl, N-methyl-8-aminoctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-
 11 ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-
 12 ethyl-8-aminoctyl and R₁ is a moiety selected from the group consisting of a hydrogen or a straight
 13 or branched C₁-20 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when
 14 R = H, n=1 and the aminomethyl functionality is para substituted; an alicyclic; single or multi-ring
 15 aromatic; single or multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring
 16 aromatic; a single or multi-ring heterocyclic, a single or multi-ring heterocyclic-substituted aliphatic;
 17 an aliphatic-substituted aromatic; and halogenated forms thereof;


19




21 wherein n can be 0 to 8, and the aminomethyl functionality can be ortho, meta or para
 22 substituted, R is hydrogen –CH₃, -CH₂CH₃, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-
 23 aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminocetyl, N-methyl-2-aminomethyl, N-methyl-3-
 24 aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-
 25 methyl-7-aminoheptyl, N-methyl-8-aminooctyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl,
 26 N-methyl-8-aminooctyl, N-ethyl-2-aminomethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-
 27 ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-ethyl-8-aminocetyl and R₁
 28 is a moiety selected from the group consisting of a hydrogen or a straight or branched C1-20
 29 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when R=H, n=1 and the
 30 aminomethyl functionality is para substituted; an alicyclic; single or multi-ring aromatic; single or
 31 multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring aromatic; a single or
 32 multi-ring heterocyclic, a single or multi-ring heterocyclic substituted aliphatic; an aliphatic-
 33 substituted aromatic; and halogenated forms thereof;

34 R₂ can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and R₄ may be
 35 the same or different and are independently selected from hydrogen, or fluorine;
 36 and halogenated forms thereof;


37



39 wherein, m and n can be 0 to 7 independently, but m cannot equal n when R₁ equals R₂ and
 40 R₃ equals R₄, o can be 2 to 4, R can be independently selected from H, -CH₃ or -CH₂CH₃, R₁ and R₂
 41 can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and R₄ may be the same or
 42 different and are independently selected from hydrogen or fluorine;




wherein, R is hydrogen, -CH₃, or -CH₂CH₃, m and n can be 0 to 7 independently and o can be 2 to 4, R₂ can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and R₄ may be the same or different and are independently selected from hydrogen or fluorine; and




wherein, R is hydrogen, -CH₃, or -CH₂CH₃, m can be 0 to 7, n can be 0 to 8 and o can be 2 to 4, R₂ can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and R₄ may be the same or different and are independently selected from hydrogen or fluorine.

18. A method of treating fungal, bacterial, viral and parasitic agents, comprising administration of a polyamine represented by at least one of the following structures:



wherein, n can be 0 to 8 and the aminomethyl functionality can be ortho, meta or para substituted, R is hydrogen, -CH₃, -CH₂CH₃, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminoctyl, N-methyl-2-aminooethyl, N-methyl-3-aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminoctyl, N-ethyl-2-aminooethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-ethyl-8-aminoctyl and R₁ is a moiety selected from the group consisting of a hydrogen or a straight or branched C1-20 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when R =H, n=1 and the aminomethyl functionality is para substituted; an alicyclic; single or multi-ring aromatic; single or multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring

15 aromatic; a single or multi-ring heterocyclic, a single or multi-ring heterocyclic-substituted aliphatic;
 16 an aliphatic-substituted aromatic; and halogenated forms thereof;
 17




19 wherein n can be 0 to 8, and the aminomethyl functionality can be ortho, meta or para
 20 substituted, R is hydrogen –CH₃, -CH₂CH₃, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-
 21 aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminocetyl, N-methyl-2-aminooethyl, N-methyl-3-
 22 aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-
 23 methyl-7-aminoheptyl, N-methyl-8-aminooctyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl,
 24 N-methyl-8-aminooctyl, N-ethyl-2-aminooethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-
 25 ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-ethyl-8-aminocetyl and R₁
 26 is a moiety selected from the group consisting of a hydrogen or a straight or branched C1-20
 27 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when R=H, n=1 and the
 28 aminomethyl functionality is para substituted; an alicyclic; single or multi-ring aromatic; single or
 29 multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring aromatic; a single or
 30 multi-ring heterocyclic, a single or multi-ring heterocyclic substituted aliphatic; an aliphatic-
 31 substituted aromatic; and halogenated forms thereof;


32 R₂ can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and R₄ may be
 33 the same or different and are independently selected from hydrogen, or fluorine;
 34 and halogenated forms thereof;

35

36 wherein, m and n can be 0 to 7 independently, but m cannot equal n when R₁ equals R₂ and
 37 R₃ equals R₄, o can be 2 to 4, R can be independently selected from H, -CH₃ or -CH₂CH₃, R₁ and R₂
 38 can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and R₄ may be the same or
 39 different and are independently selected from hydrogen or fluorine;



wherein, R is hydrogen, -CH₃, or -CH₂CH₃, m and n can be 0 to 7 independently and o can be 2 to 4, R₂ can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and R₄ may be the same or different and are independently selected from hydrogen or fluorine; and



2 wherein, R is hydrogen, -CH₃, or -CH₂CH₃, m can be 0 to 7, n can be 0 to 8 and o
3 can be 2 to 4, R₂ can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and
4 R₄ may be the same or different and are independently selected from hydrogen or fluorine.

5 19. A method according to claim 11 wherein said condition is selected from the group consisting of cancer, mucositis, asthma, inflammation, autoimmune disease, psoriasis, restentosis, rheumatoid arthritis, scleroderma, systemic and cutaneous lupus erythematosus, Type I insulin dependent diabetes, tissue transplantation, osteoporosis, hyperparathyroidism, treatment of peptic ulcer, glaucoma, Alzheimer's disease, Crohn's disease and other inflammatory bowel diseases.

10

20. A method of treating one or more conditions associated with cellular proliferation comprising administration of at least one of B, T or U shown in Figure 1.

21. The method of claim 20 wherein said administration is systemic.

15

22. The method of claim 20 or 21 wherein said administration is oral.

23. The method of claim 20 or 21 wherein said administration is via a time-release vehicle.

5 24. A method of inhibiting hair growth comprising topical administration of at least one of B, T or U shown in Figure 1 to a subject in need of hair growth inhibition.

25. The method of claim 20 wherein said B, T or U is formulated as a cosmetic.

10 26. A method of inhibiting hair loss (alopecia) comprising topical administration of at least one of B, T or U shown in Figure 1 to a subject undergoing radiation or chemotherapy.

15 27. A method of treating a member selected from the group consisting of fungal, bacterial, viral and parasitic agents, comprising administration of at least one of B, T or U shown in Figure 1.

20 28. A method according to claim 20 wherein said condition is selected from the group consisting of cancer, mucositis, asthma, inflammation, autoimmune disease, psoriasis, restentosis, rheumatoid arthritis, scleroderma, systemic and cutaneous lupus erythematosus, Type I insulin dependent diabetes, tissue transplantation, osteoporosis, hyperparathyroidism, treatment of peptic ulcer, glaucoma, Alzheimer's disease, Crohn's disease and inflammatory bowel diseases.

25 29. The polyamine of claim 1 wherein said structure is that of compound Q as shown in Figure 1.

30. The polyamine of claim 1 wherein said structure is that of compound B as shown in Figure 1.

31. The polyamine of claim 1 wherein said structure is that of compound M as shown in Figure 1.

32. The polyamine of claim 1 wherein said structure T as shown in Figure 1.

33. The polyamine of claim 1 wherein said structure U as shown in Figure 1.